{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:42:29Z","timestamp":1786221749508,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Photodiagnosis and Photodynamic Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.pdpdt.2026.105537","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:06:37Z","timestamp":1780531597000},"page":"105537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rapid vascular pruning and remodeling in refractory type 1 macular neovascularization: A quantitative swept-source OCT angiography study of Faricimab"],"prefix":"10.1016","volume":"60","author":[{"given":"Wenqi","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinguo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-4026","authenticated-orcid":false,"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.pdpdt.2026.105537_bib0001","doi-asserted-by":"crossref","first-page":"e1175","DOI":"10.1016\/S2214-109X(25)00143-3","article-title":"Global burden of vision impairment due to age-related macular degeneration, 1990-2021, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"13","year":"2025","journal-title":"Lancet Glob Health."},{"issue":"5","key":"10.1016\/j.pdpdt.2026.105537_bib0002","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature Study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology."},{"issue":"3","key":"10.1016\/j.pdpdt.2026.105537_bib0003","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ophtha.2020.08.006","article-title":"Polypoidal choroidal vasculopathy: consensus nomenclature and non-indocyanine green angiograph diagnostic criteria from the Asia-Pacific Ocular Imaging Society PCV Workgroup","volume":"128","author":"Cheung","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pdpdt.2026.105537_bib0004","volume":"29","author":"Lai","year":"2025","journal-title":"Asia Pac. J. Ophthalmol. (Phila)"},{"issue":"11","key":"10.1016\/j.pdpdt.2026.105537_bib0005","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/bjophthalmol-2013-303513","article-title":"Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration","volume":"97","author":"Krebs","year":"2013","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.pdpdt.2026.105537_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","article-title":"Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration","volume":"59","author":"Finger","year":"2014","journal-title":"Surv. Ophthalmol."},{"issue":"7","key":"10.1016\/j.pdpdt.2026.105537_bib0007","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.pdpdt.2026.105537_bib0008","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","article-title":"Faricimab treat-and-extend dosing for macular edema due to retinal vein occlusion: 72-week results from the BALATON and COMINO trials","volume":"9","author":"Danzig","year":"2025","journal-title":"Ophthalmol. Retina"},{"issue":"10326","key":"10.1016\/j.pdpdt.2026.105537_bib0009","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pdpdt.2026.105537_bib0010","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of Faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"issue":"16","key":"10.1016\/j.pdpdt.2026.105537_bib0011","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","article-title":"Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy","volume":"38","author":"Goodchild","year":"2024","journal-title":"Eye (Lond)"},{"issue":"15","key":"10.1016\/j.pdpdt.2026.105537_bib0012","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.3390\/jcm14155412","article-title":"Sagong M. Real-world efficacy and durability of Faricimab in aflibercept-resistant neovascular age-related macular degeneration","volume":"14","author":"Jeong","year":"2025","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.pdpdt.2026.105537_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-0270(96)00080-5","article-title":"Fractal methods and results in cellular morphology\u2013dimensions, lacunarity and multifractals","volume":"69","author":"Jr","year":"1996","journal-title":"J. Neurosci. Methods"},{"issue":"9","key":"10.1016\/j.pdpdt.2026.105537_bib0014","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/s41433-024-03007-2","article-title":"Qualitative and quantitative comparisons of type 1 macular neovascularizations between pachychoroid neovasculopathy and neovascular age-related macular degeneration using optical coherence tomography angiography","volume":"38","author":"Yan\u0131k","year":"2024","journal-title":"Eye (Lond)"},{"issue":"17","key":"10.1016\/j.pdpdt.2026.105537_bib0015","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Lond)"},{"issue":"8","key":"10.1016\/j.pdpdt.2026.105537_bib0016","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3928\/23258160-20250304-02","article-title":"Early outcomes after initiation of faricimab for neovascular age-related macular degeneration","volume":"56","author":"Ali","year":"2025","journal-title":"Ophthalmic. Surg. Lasers. ImAging Retina"},{"issue":"1","key":"10.1016\/j.pdpdt.2026.105537_bib0017","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.survophthal.2024.09.011","article-title":"Choroidal thickness after anti-vascular endothelial growth factor in typical neovascular age-related macular degeneration - A systematic review and meta-analysis","volume":"70","author":"Hoven","year":"2025","journal-title":"Surv. Ophthalmol."},{"issue":"5","key":"10.1016\/j.pdpdt.2026.105537_bib0018","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.pdpdt.2026.105537_bib0019","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/IAE.0000000000000465","article-title":"Refractory intraretinal or subretinal fluid in neovascular age-related macular degeneration treated with intravitreal ranibizumab: functional and structural outcome","volume":"35","author":"Gianniou","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.pdpdt.2026.105537_bib0020","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2024","journal-title":"Front. Ophthalmol. (Lausanne)"},{"issue":"10","key":"10.1016\/j.pdpdt.2026.105537_bib0021","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s40123-024-01005-x","article-title":"Faricimab in neovascular AMD complicated by pigment epithelium detachment: an AI-assisted evaluation of early morphological changes","volume":"13","author":"Veritti","year":"2024","journal-title":"Ophthalmol. Ther."},{"issue":"1","key":"10.1016\/j.pdpdt.2026.105537_bib0022","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40942-025-00691-4","article-title":"Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA","volume":"11","author":"Heinke","year":"2025","journal-title":"Int. J. Retina Vitreous."},{"issue":"11","key":"10.1016\/j.pdpdt.2026.105537_bib0023","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBo Mol. Med."},{"issue":"5","key":"10.1016\/j.pdpdt.2026.105537_bib0024","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00417-024-06695-4","article-title":"Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases","volume":"263","author":"Chaudhary","year":"2025","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"issue":"9","key":"10.1016\/j.pdpdt.2026.105537_bib0025","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamaophthalmol.2020.2685","article-title":"Safety and efficacy of different doses and regimens of Faricimab vs Ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial","volume":"138","author":"Sahni","year":"2020","journal-title":"JAMa Ophthalmol."},{"issue":"3","key":"10.1016\/j.pdpdt.2026.105537_bib0026","first-page":"205","article-title":"Fractal and multifractal analysis of human retinal vascular network: a review","volume":"3","author":"\u0162\u0103lu","year":"2011","journal-title":"HVM Bioflux"},{"issue":"1","key":"10.1016\/j.pdpdt.2026.105537_bib0027","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1038\/s41598-023-33936-z","article-title":"Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration","volume":"13","author":"Kuranami","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.pdpdt.2026.105537_bib0028","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/s41433-024-03253-4","article-title":"Pachychoroid disease: review and update","volume":"39","author":"Cheung","year":"2025","journal-title":"Eye (Lond)"}],"container-title":["Photodiagnosis and Photodynamic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100026002048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100026002048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T19:53:05Z","timestamp":1786218785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1572100026002048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":28,"alternative-id":["S1572100026002048"],"URL":"https:\/\/doi.org\/10.1016\/j.pdpdt.2026.105537","relation":{},"ISSN":["1572-1000"],"issn-type":[{"value":"1572-1000","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapid vascular pruning and remodeling in refractory type 1 macular neovascularization: A quantitative swept-source OCT angiography study of Faricimab","name":"articletitle","label":"Article Title"},{"value":"Photodiagnosis and Photodynamic Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pdpdt.2026.105537","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105537"}}